INS and cancer: Compared with other insulin analogues, insulin glargine use was associated with a lower odds of overall cancer in a random-effects model (OR 0.76, 95% CI 0.62 to 0.93, P = 0.008), with significant heterogeneity (P = 0.003, I2 = 79.0%).